Currentblue cross blue shield - tennesseePolicy N/A

Hepatitis C screening, testing, and monitoring

Defines coverage criteria for Hepatitis C virus (HCV) screening, diagnostic testing (antibody, RNA/NAT), genotype testing, and monitoring before, during, and after treatment for members of the plan.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyHepatitis C screening, testing, and monitoring

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain and document confirmatory quantitative HCV RNA testing after a positive HCV antibody test and document baseline labs and genotype prior to initiating therapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

one-timeHCV testing covered for all individuals >18 years

baseline→4→EOT→12/24wRNA monitoring schedule

≥12wSVR confirmation timing

AnnualTesting frequency for ongoing risk groups

18+Guideline citations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

One-time lifetime screening

Covered when ANY of the following apply:

One-time lifetime testing for adults: One-time testing for HCV infection meets coverage criteria for all individuals over 18 years of age.

One-time testing for recognized conditions/exposures (post-exposure)

Covered when ANY of the listed recognized conditions or exposures are present:

Recognized conditions/exposures: Illicit intranasal or injectable drug use; receipt of clotting factor concentrates produced before 1987; history of hemodialysis; evidence of liver disease (clinical presentation or persistently abnormal ALT or abnormal liver function studies); presence of HIV infection; receipt of an organ transplant before July 1992; receipt of a blood transfusion or blood component before July 1992; individuals notified that they received blood from a donor who later tested positive for HCV infection; history of incarceration; receipt of a tattoo in an unregulated setting; healthcare, emergency medical, and public safety workers after needle sticks, sharps, or mucosal exposures to HCV-positive blood; children born to an HCV-positive individual; current sexual partners of HCV-infected persons.

List assembled from policy itemization of recognized conditions and exposures.

Routine periodic testing for individuals with ongoing risk factors

Covered while risk factors persist when ANY of the following are present:

Ongoing risk factors: Individuals who currently inject drugs and share needles, syringes, or other drug preparation equipment; individuals receiving ongoing hemodialysis; individuals engaging in high-risk sexual behavior.

Routine periodic HCV testing meets coverage criteria while these risk factors persist.

Genotype and RNA testing

Covered when ALL of the following are met:

Genotype prior to treatment: One-time testing for HCV genotype meets coverage criteria prior to initiation of treatment to guide selection of the antiviral regimen.

Genotyping recommended where it informs regimen selection; per CASL/AGA guidance.

HCV RNA testing schedule: Quantitative HCV RNA testing (NAT) meets coverage criteria prior to initiation of therapy, after 4 weeks of therapy, at the end of treatment, and at 12 and 24 weeks after completion of treatment.

RNA testing also used to determine spontaneous clearance in acute infection; monitoring every 4–8 weeks for 6–12 months may be used in acute HCV.

Screening recommendations (CDC-aligned)

CDC-recommended testing covered for the listed groups:

CDC one-time testing: One-time HCV testing is recommended regardless of age for persons with HIV and for people who ever injected drugs and shared needles/syringes or other drug preparation equipment.

CDC recommends initial testing with an FDA-approved anti-HCV assay and reflex HCV NAT to confirm active infection.

CDC risk-based testing: Testing recommended for persons who ever received maintenance hemodialysis, have persistently abnormal ALT levels, received clotting factor concentrates before 1987, received transfusion/organ transplant before July 1992, were notified of receiving blood from a later-positive donor, healthcare/emergency/public safety personnel after exposures, and children born to HCV-infected mothers; repeat testing is recommended for those with ongoing risk behaviors.

CDC endorses testing any person who requests hepatitis C testing regardless of disclosure of risk.

Covered indications and management

Covered screening and diagnostic testing is supported when ANY of the following apply (per referenced guidelines):

Screening indications: Includes one-time testing for adults (USPSTF 18–79) and CDC/AASLD recommendations for one-time or routine opt-out testing for adults aged ≥18; targeted testing for persons with risk factors or high-prevalence populations; offer testing to any person who requests it.

References: USPSTF, CDC, AASLD-IDSA, WHO, WGO.

Diagnostic confirmation: After a positive HCV-antibody test, reflex HCV RNA NAT/PCR testing is required to differentiate active versus resolved infection; perform HCV RNA testing for suspected recent exposure or immunocompromised persons.

Reflex NAT recommended by CDC and testing guidance.

Pre-treatment evaluation: Before initiating DAA therapy, obtain within 6 months: CBC, INR, hepatic function panel (albumin, bilirubin, ALT, AST, ALP) and eGFR; obtain quantitative HCV RNA and genotype if a non-pangenotypic DAA is planned.within 6 months

Testing and monitoring recommendations

Coverage-related clinical recommendations and testing that should be available prior to and after HCV therapy

Initial diagnostic and pre-treatment testing: Determine HCV RNA and HCV genotype/subtype and perform baseline routine bloodwork including CBC, liver enzymes (ALT, AST, ALP), and liver function tests (bilirubin, INR, albumin) before initiating therapy.

CASL and AGA recommend these tests as part of the initial workup.

SVR confirmation: Confirm sustained virologic response (SVR) by undetectable HCV RNA at 12 weeks after completing an all-oral DAA regimen.12 weeks post-treatment

AGA best practice statements endorse SVR confirmation at 12 weeks; consideration of 24 and 48 week testing varies by circumstance.

Extended RNA testing: Consider HCV RNA testing at 24 weeks post-treatment on an individual basis and routine confirmation at 48 weeks when indicated; routine periodic RNA testing beyond 48 weeks is not supported except for patients with ongoing risk factors for reinfection (annual testing suggested for those at ongoing risk).

A hepatitis C vaccine is not available at this time. Although multiple vaccine candidates are under development, significant barriers—such as viral diversity and limited models for vaccine testing—have prevented an approved HCV vaccine to date.

The American Association for the Study of Liver Diseases (AASLD) advises that routine repeat HCV viral load testing outside of antiviral therapy is not recommended, because such repeated virologic testing generally does not change clinical management or outcomes.

The European Association for the Study of the Liver (EASL) states that while determination of HCV genotype/subtype can be useful where available, testing for HCV resistance prior to treatment is not recommended when it does not affect access to care or treatment decisions.

This bibliographic section cites guideline and evidence sources used to inform policy but does not specify any explicit coverage exclusions.

Per AASLD guidance, repeating quantitative HCV viral load testing in patients who are not receiving antiviral therapy is not considered clinically useful and is therefore not routinely indicated.

The Canadian Task Force on Preventive Health Care (CTFPHC) recommends against screening adults who are not at elevated risk; screening asymptomatic, low-risk adults is not recommended.

The referenced section is a list of literature and guideline citations and does not itself contain statements designating services as not medically necessary.

Coding — Diagnostic and Monitoring Codes

Recommended diagnostic testsmixed

HCV antibody (serology)	Initial serological test for HCV exposure (anti-HCV) — RDT or laboratory immunoassay
HCV NAT / PCR (qualitative and quantitative)	Nucleic acid test to detect HCV RNA for confirmation of active infection and for baseline viral load
HCV genotype testing	Genotype and subtype testing recommended when non-pangenotypic DAA may be used

Baseline and monitoring laboratory testsmixed

CBC	Complete blood count — pre-treatment baseline and monitoring
INR	International normalized ratio — baseline and monitoring
Hepatic function panel	Serum albumin, total and direct bilirubin, ALT, AST, alkaline phosphatase
eGFR / Creatinine	Renal function assessment (eGFR; creatinine listed)

Liver disease severity assessmentmixed

Transient elastography	Noninvasive fibrosis assessment (eg, FibroScan)
Liver imaging (US/CT)	Imaging for liver disease assessment and HCC surveillance

Laboratory-developed tests (LDTs)mixed

No codes listed

SVR assessment timing

Recommended timingQuantitative HCV viral load testing recommended 12 or more weeks after completion of therapy to document sustained virologic response (SVR)

PurposeUsed to confirm SVR, a proxy for elimination (cure) of chronic HCV infection

Guideline basisAASLD-IDSA and referenced reimbursement policy recommend testing at >=12 weeks post-therapy

Pre-treatment labs timing

Recommended windowLaboratory tests (CBC, INR, hepatic function panel, eGFR) recommended within 6 months prior to starting DAA therapy

Required virologic testing prior to therapyQuantitative HCV RNA (viral load) should be obtained any time prior to starting DAA therapy

Genotype guidanceIf a non-pangenotypic DAA will be prescribed, test for HCV genotype and subtype prior to therapy

Provider Actions — Authorization, Documentation, and Operational Notes

Documentation Required

SVR and post-treatment monitoring documentation

Quantitative HCV RNA testing 12 or more weeks after completion of antiviral therapy is recommended to document sustained virologic response (SVR), which is considered a proxy for cure. Routine confirmation of SVR at 48 weeks post-treatment may be considered; testing at 24 weeks can be individualized. For patients with ongoing risk factors, periodic HCV RNA testing is recommended to monitor for reinfection. For those who fail treatment, disease progression assessment (CBC, hepatic function panel, INR) every 6–12 months and HCC surveillance for patients with cirrhosis are recommended.

SVR = undetectable HCV RNA at 12 weeks after completion of therapy (standard confirmation).
Consider SVR confirmation at 48 weeks; 24-week testing individualized.
Periodic RNA testing for patients with ongoing risk factors (annual or as clinically indicated).
If treatment failed and not retreated, monitor CBC, hepatic panel, INR every 6–12 months; HCC surveillance every 6 months for cirrhosis.

Documentation Required

Pre-treatment testing and SVR confirmation

Prior to initiation of direct-acting antiviral (DAA) therapy, document baseline quantitative HCV RNA (viral load), HCV genotype/subtype when it may affect regimen selection, and baseline hepatic labs (CBC, hepatic function panel including albumin, total/direct bilirubin, ALT, AST, ALP, INR) and eGFR. After treatment completion, document follow-up quantitative HCV RNA testing as above to confirm SVR.

Baseline labs within 6 months prior to starting DAA: CBC, INR, hepatic function panel, eGFR.
Baseline quantitative HCV RNA (viral load) prior to therapy initiation.
Genotype/subtype testing if a non-pangenotypic DAA is being considered or if results will change management.
Documentation of initial HCV-antibody and reflex quantitative HCV RNA when applicable.

Prior Authorization

Prior authorization — not addressed in this section

This section does not establish or specify prior authorization rules; coverage and any authorization requirements are determined by the member's specific benefit plan and applicable Medicare/Medicaid rules.

Benefit eligibility at time of request drives coverage decisions.
Consult the member's benefit plan or prior authorization criteria elsewhere in the payer policy set for any authorization requirements.

Note

Benefit eligibility drives coverage

Coverage decisions depend on the individual's benefit coverage at the time of request; Medicare and Medicaid specifications may further modify coverage.

Requests inconsistent with benefit coverage at the time of request may be denied.
Refer to Section VII for Medicare/Medicaid specifications when applicable.

Denial Risk

No denial triggers are specified in these references

No explicit denial triggers are specified within this excerpt. The referenced guideline citations provide clinical context but do not list payer-specific denial criteria.

Absence of required confirmatory testing (e.g., failure to perform HCV RNA after a positive antibody) may affect documentation of active infection and thus coverage decisions under benefit rules.
Operational denial criteria, if any, will be found in the payer's utilization management or prior authorization sections.

Documentation Required

Required documentation

Required documentation for testing and treatment decisions should include the indication for testing, initial HCV-antibody result, reflex or confirmatory quantitative HCV RNA/PCR results, baseline viral load, genotype/subtype when relevant, and baseline hepatic laboratory values.

Document indication for testing (screening vs. exposure vs. monitoring vs. pre-treatment).
Provide prior positive antibody or exposure history when ordering NAT/PCR to confirm active infection.
Include baseline CBC, hepatic function panel (albumin, bilirubin, ALT, AST, ALP), INR, and eGFR in the pre-treatment record.
Document follow-up quantitative HCV RNA results at recommended intervals (on-therapy monitoring, end of treatment, and 12+ weeks post-treatment for SVR).

Note

No documentation requirements are specified in these reference citations

Some citations in this excerpt are bibliographic and do not specify payer documentation requirements or operational rules.

These references offer clinical guidance but do not replace payer-specific documentation or prior authorization policies.
Operational requirements (forms, timelines) must be obtained from the payer's administrative guidance.

Step Therapy

Step therapy — No step therapy requirements described here

No step therapy requirements or specific stepwise medication sequencing rules are described in this section or in the cited guideline excerpts.

If step therapy rules apply, they will be defined in payer-specific pharmacy or clinical utilization policies.
Clinicians should verify plan-level pharmacy management rules prior to prescribing.

Documentation Required

Repeat viral load testing outside therapy

AASLD recommends not repeating hepatitis C viral load testing outside of antiviral therapy because results generally do not change clinical management or outcomes; repeat testing is recommended for those with ongoing risk factors or when clinically indicated.

Do not perform routine repeat HCV RNA testing outside of antiviral therapy unless ongoing risk of reinfection or other clinical indication exists.
Annual testing may be suggested for persons with ongoing exposure risk per CASL guidance.

Note

No step therapy rules are provided in these references

No step therapy rules are provided in these guideline citations; this section is bibliographic and clinical in focus rather than prescribing utilization management rules.

Payer-level step therapy policies, if any, are maintained separately and should be consulted for operational requirements.
Clinical guidance here emphasizes diagnostic and monitoring testing rather than formulary sequencing.

Definitions and Key Terms

Sustained virologic response (SVR)

DefinitionUndetectable HCV RNA 12 weeks after completion of therapy, used as a proxy for elimination of HCV RNA (SVR)

MeasurementDocumented by quantitative HCV RNA (NAT/PCR) at ≥12 weeks post-treatment

Clinical significanceSVR is the accepted marker of cure and primary goal of DAA therapy

HCV genotype

DefinitionGenetic classification of hepatitis C virus; major genotypes influence regimen selection, dosing, and duration

Clinical useGenotype and subtype (e.g., 1a vs 1b) help tailor therapy prior to initiation, especially if non-pangenotypic DAA is considered

Guideline noteCASL and AGA recommend genotyping as part of the initial workup when it may alter treatment

Active HCV infection

DefinitionPresence of HCV RNA detectable by nucleic acid test (NAT/PCR); anti-HCV antibody positive with HCV RNA positive indicates active infection

ConfirmationAfter a positive anti-HCV test, reflex HCV RNA NAT/PCR is required to differentiate active versus resolved infection

Special considerationsHCV-RNA testing is recommended for suspected recent exposure and immunocompromised persons

Assessment of liver disease severity

ApproachUse noninvasive serum biomarkers, elastography (transient elastography), or liver imaging (ultrasound/CT) to determine cirrhosis and guide management

Common testsRoutine blood tests (ALT, AST, albumin, bilirubin, INR, CBC with platelets) and serum fibrosis marker panels frequently used

Role of biopsyLiver biopsy is rarely required and reserved when other causes of liver disease are suspected

SVR

SVR definition (AGA)Sustained virologic response (SVR): undetectable HCV RNA at 12 weeks after completion of an all-oral DAA treatment regimen

Additional monitoringAGA recommends routine confirmation of SVR at 48 weeks and individualized consideration of testing at 24 weeks; periodic testing beyond 48 weeks only for ongoing risk

Measurement methodConfirmed by quantitative HCV RNA testing (NAT/PCR)

HCV genotype/subtype

DefinitionHCV genotype and subtype: viral genetic classification (e.g., 1a vs 1b) used to tailor therapy prior to initiation

When to testGenotyping is recommended before starting therapy when it may affect regimen choice (CASL/AGA guidance)

ImpactGenotype can determine suitability of certain DAAs and influence treatment duration and dosing

Hepatitis C diagnostic testing

ScopeReference materials on diagnostic testing strategies and core concepts, including confirmatory testing algorithms and rapid diagnostic tests

Initial testingRecommend HCV-antibody testing with reflex HCV RNA PCR for initial diagnosis

Rapid testsPoint-of-care rapid diagnostic tests (serum, plasma, fingerstick, saliva) can be used to facilitate anti-HCV antibody screening where appropriate

OpenPayer

Hepatitis C screening, testing, and monitoring

Coverage Criteria — Screening, Diagnostic, and Monitoring

Coding — Diagnostic and Monitoring Codes

Provider Actions — Authorization, Documentation, and Operational Notes

Background — Hepatitis C Overview

Definitions and Key Terms